Company intelligence / Profile preview

AFG BioSolutions

Gaithersburg, Maryland, USA

Ownership: Private
Development stage: Other

Overview

AFG BioSolutions was a Maryland-based biotechnology company focused on developing vaccines and therapeutics for biodefense and public health threats. The company's primary focus was the development of recombinant human butyrylcholinesterase (rBChE) as a countermeasure against nerve agents and organophosphate pesticides. In 2006, AFG BioSolutions was acquired by Emergent BioSolutions for approximately $7 million to bolster its biodefense portfolio and R&D capabilities. The acquisition integrated AFG's expertise in protein expression and its pipeline of biodefense candidates into Emergent's larger infrastructure.

Therapeutic areas: Neurology
Modalities: Recombinant proteinVaccine
Industry: Biotech

Partnerships

U.S. Department of Defense

Beyond the preview

Go deeper on AFG BioSolutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AFG BioSolutions.

Explore the full profile